About Viewray

Meet Our Team

At ViewRay®, our vision is clear—we’re dedicated to giving clinicians new and better ways to treat cancer with radiation therapy. Meet our industry leaders committed to innovation excellence.

Chris A. Raanes

CEO & President

With extensive experience in the medical device field, Chris Raanes has held executive positions at companies such as Accuray and PerkinElmer Optoelectronics. As executive vice president and chief operating officer at Accuray, Raanes was instrumental in transforming the company from a start-up niche player into the number three vendor in the radiation therapy industry. He holds an MSEE from the Massachusetts Institute of Technology.

James F. Dempsey, PhD

Chief Scientific Officer

Company founder and inventor of the ViewRay technology, Jim Dempsey guides the scientific and technical aspects of the MRIdian system’s development. Dempsey holds a PhD in nuclear chemistry from Washington University. He is a board-certified medical physicist and former associate professor of radiation oncology at the University of Florida.

Doug Keare

Chief Operating Officer

Doug brings over twenty years of technology and medical device executive experience, including roles at Accuray and ADAC Labs. He has led successful customer-focused operations at numerous companies and as VP of Quality at ADAC Labs, led the company to win the Malcolm Baldrige National Quality Award. He received a BA from Dartmouth College and an MBA from Stanford University’s Graduate School of Business.

Ajay Bansal

Chief Financial Officer

Mr. Bansal brings to ViewRay nearly 30 years of life sciences industry experience, spanning the areas of finance, commercialization, strategic planning and business development. Since 2003, Mr. Bansal has served as CFO of various life sciences companies, raising over $1 billion of capital. Most recently, he served as CFO of Onconova Therapeutics, where he led the company’s initial public offering in 2013. Prior to that, Mr. Bansal served as CFO of Complete Genomics, where he led the company’s initial public offering in 2010. Previously, Mr. Bansal was a partner at Mehta Partners, LLC. where he provided strategic advisory services to the firm’s biotechnology and pharmaceutical clients. Earlier in his career, Mr. Bansal worked in strategy, sales and marketing for Novartis Pharmaceuticals and held positions with leading consulting firms, including McKinsey & Company. He received Masters degrees in both management and operations research from Northwestern University.

Martin Fuss, MD

Chief Medical Officer

Dr. Martin Fuss is Chief Medical Officer and the Executive Director of the Clinical Cooperative Think Tank (C2T2) as well as a practicing radiation oncologist and partner in Radiation Oncology Specialists in Tualatin, OR. Dr. Fuss graduated from medical school at the University of Heidelberg, Germany where he also obtained his doctorate degree in human imaging assessing blood flow changes in the brain using functional MRI techniques (DCE-MRI). He underwent his specialty training in radiation oncology at the University of Heidelberg and at the German Cancer Research Center (dkfz). During his residency, he was invited as a research fellow at the Proton Radiation Therapy facility at Loma Linda University Medical Center in Loma Linda, CA. From 2000 to 2006 he was a faculty member at The University of Texas Health Science Center at San Antonio, San Antonio, TX (UTHSCSA). Prior to moving into private practice, he was Professor and Vice Chair of the Department of Radiation Medicine at Oregon Health & Science University (OHSU) from 2006-2013.

Mary O’Byrne

Vice President and Chief Counsel

Ms. O’Byrne brings over 30 years of legal experience in representing Silicon Valley companies, including her most recent position as Vice President and Chief Counsel of Varian Medical System’s Radiation Oncology Business Unit. Her 14 years at Varian spanned the full range of radiation oncology legal issues, including sales, marketing, regulatory compliance, human resources, and dispute resolution. Ms. O’Byrne was a member of Radiation Oncology’s Executive Staff and regularly reported to Varian’s Board of Directors. Prior to Varian, Ms. O’Byrne worked as Senior Corporate Counsel for PeopleSoft (before it was acquired by Oracle) handling its strategic alliance initiatives and regional sales and consulting businesses, as well as Vice President and General Counsel of pioneering web-site design company, NetObjects. Her early experience also included legal positions with Amdahl Corporation (acquired by Futjisu Ltd.) and various high tech law firms handling complex business litigation. Ms. O’Byrne has a Bachelor of Arts degree from the University of Illinois at Chicago and her Juris Doctor degree from the University of California, Hastings College of the Law.

Mark Arnold

Senior Vice President of Marketing

Mr. Arnold comes to ViewRay with nearly 20 years marketing experience within the oncology life sciences field. As former Vice President of Global Marketing at Elekta, Mr. Arnold led the commercialization efforts for the linear accelerator, oncology information system and treatment planning software businesses. Mr. Arnold also held the position of Senior Director of Marketing at Accuray Incorporated, overseeing product management, product marketing and marketing communications responsibilities for the CyberKnife® product portfolio.

A New Kind of Medical Technology Company

ViewRay was founded on the belief that enhanced real-time visualization combined with on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients.

MRI-guided radiation therapy was conceived by company founder James F. Dempsey, PhD, while he was a member of the radiation oncology faculty at the University of Florida in 2004. And ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies.

In Brief

Founded: 2004
Headquarters: Cleveland, Ohio
Corporate status: Publicly held
Market: Radiation therapy and imaging technologies

Board of Directors

Scientific Advisory Board

John Bayouth, PhD, University of Wisconsin, Madison
Jeffrey Bradley, MD, Washington University, St. Louis, Missouri
Jürgen Debus, Prof. Dr., NCT Heidelberg, Germany
Carlos A. Perez, MD, Washington University, St. Louis, Missouri

Ben Slotman, MD, VU University Medical Center, Amsterdam
Michael Steinberg, MD, University of California, Los Angeles
Vincenzo Valentini, MD, Universita Cattolica S. Cuore Roma
Hong-Gyun Wu, MD, Seoul National University Hospital, Seoul,South Korea

Contact Us

MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. Over 3000 treatments have been delivered at centers world-wide since 2011.

Contact us to learn more about how we are making the invisible, visible every day across the world.

Contact Us


Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy